The Lynx Group
Cholangiocarcinoma News

Videos

Key CCA Abstracts Presented at the 2021 Annual Meeting of the Society of Interventional Oncology and Society of Interventional Radiology
Videos — April 14, 2021
Bruno Odisio, MD, from the MD Anderson Medical Center, provides expert commentary on key abstracts presented at the 2021 annual meetings of the Society of Interventional Oncology and Society of Interventional Radiology. Dr Odisio presents information on 6 abstracts that highlight new data on diagnostic and interventional modalities for patients with cholangiocarcinoma.
Read More

Selecting Among the FGFR Inhibitors in FGFR2 Fusion–Positive Cholangiocarcinoma

The Role of FGFR Inhibitors in Treating FGFR2 Fusion–Positive Cholangiocarcinoma
Videos — February 22, 2021
Drs Javle and Hollebecque review the phase 2 clinical trial efficacy data of pemigatinib, infigratinib, and futibatinib as second-line therapy of FGFR2 fusion–positive cholangiocarcinoma, and explore use of these agents in the first-line and adjuvant settings.
Read More

The Role of FGFR Genetic Alterations in Cholangiocarcinoma
Videos — January 21, 2021
A discussion of the molecular biology of the FGFR pathway in the growth and development of cholangiocarcinoma.
Read More

Key Cholangiocarcinoma Abstracts Presented at ASCO GI 2021
Videos — January 20, 2021
Rachna Shroff, MD, from the University of Arizona Cancer Center, presents her insights into important new data in cholangiocarcinoma from ASCO GI 2021. New evidence is being presented on FGFR inhibitors, targeted therapies, chemotherapy in second-line, combination therapy, immunotherapy, and more.
Read More

Top 10 Abstracts from ASCO 2020 with Milind Javle
Videos — June 3, 2020
Treatment options for cholangiocarcinoma continue to evolve. Milind Javle, MD, from MD Anderson Cancer Center, discusses some interesting abstracts from the ASCO 2020 meeting.
Read More

Using FGFR Inhibitors in Clinical Practice
Videos — May 14, 2020
Dr Angela Lamarca discusses the use of FGFR inhibitors in daily practice. Their use will depend largely on data from currently ongoing second- and first-line clinical trials. She suggests that consideration should be given to their use in combination with chemotherapy and/or as maintenance therapy after first-line chemotherapy. Dr Milind Javle summarizes the field, suggesting that a time may come when patients with CCA are never treated with chemotherapy at all. Pemigatinib was FDA approved as second-line therapy in cholangiocarcinoma in May 2020.
Read More

Toxicities Associated with FGFR Inhibitors
Videos — April 2, 2020
Dr Vaibhav Sahai reviews the toxicities that have been encountered in clinical trials with FGFR inhibitors. He suggests that most of these adverse events are class effects and include hyperphosphatemia (which is relatively easy to manage with dietary restrictions and phosphate-binding agents), nail and hair changes, stomatitis, and retinal epithelial changes. In contrast, Dr Angela LaMarca considers the adverse events associated with chemotherapy, including myelosuppression, nausea, vomiting, diarrhea, and others. Dr Milind Javle suggests that the toxicities encountered with chemotherapy are significantly worse than those with FGFR inhibitors.
Read More

Effective Targeted Therapies in CCA: IDH1 and FGFR
Videos — March 10, 2020
Dr Angela Lamarca reviews the current clinical trials with FGFR inhibitors, particularly those with patients with FGFR2 fusion and other genetic aberrations. Dr Vaibhav Sahai highlights those FGFR inhibitors that are nonselective and those that are selective for FGFR1-4, and discusses the clinical trial results with the selective inhibitors, including pemigatinib and infigratinib. He remarks that the response rates and progression-free survival in these trials have been remarkable, far better than what is seen with chemotherapy.
Read More

Managing CCA Patients While Waiting for Molecular Biomarker Testing Results
Videos — February 21, 2020
Dr Vaibhav Sahai and Dr Angela Lamarca consider options for managing patients with CCA while awaiting results from biomarker testing, which can take 3 to 6 weeks. They discuss starting these patients on first-line chemotherapy and then switching appropriate patients to second-line targeted therapy, and also speak to the increased utility of next-generation sequencing in CCA.
Read More

Page 1 of 2

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: